Product Description
Amitriptylinoxide is an organic tricyclic compound. Amitriptylinoxide has been used in trials studying Major Depression. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Amitriptylinoxide)
Mechanisms of Action: NET Blocker,SERT Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: HolsboerMaschmeyer NeuroChemie
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Depressive Disorder, Major|Psychotic Disorders|Bipolar Disorder
Phase 3: Tic Disorders|Schizophrenia|Dementia|Depressive Disorder|Psychophysiologic Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GAP | P3 |
Terminated |
Depressive Disorder|Dementia|Psychophysiologic Disorders|Tic Disorders|Schizophrenia |
2017-06-28 |
|
NCT02237937 | P4 |
Unknown status |
Depressive Disorder, Major |
2014-12-01 |
|
ABCB1 Clinical Study | P4 |
Active, not recruiting |
Bipolar Disorder|Depressive Disorder, Major|Psychotic Disorders |
2014-01-30 |